


IN THE CLAIMS

Cancel claims 9 and 11.

Insert the following set of claims with amended claims 1, 4-8 and 12, unamended claims 2 and 3, and newly added claims 13-16. A marked-up version of the amended claims is attached as an appendix to this paper.

*B2*  
1. (amended) A crystalline form of the monomethanesulfonic acid addition salt of a compound of formula I,



(I)

which is non-hygroscopic in a glass climatic chamber at 25 °C and relative humidities up to and including 93%.

2. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 95% by weight crystals of the  $\beta$ -modification and remains dry at 93% relative humidity and 25°C.

3. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 99% by weight crystals of the  $\beta$ -modification and remains dry at 93% relative humidity and 25°C.

4. (amended) A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 99% by weight crystals of the  $\beta$ -modification and has a melting point below 225°C.

5. (amended) A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 99% by weight crystals of the  $\beta$ -modification and has a melting point of less than 217°C, defined as the start of melting in the differential scanning calorimetry thermogram.


6. (amended) A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which shows on X-ray diffraction a peak at an angle of refraction  $2\theta$  of 20°, said peak having a relative line intensity of about 65 as compared to the most intense line in the diagram.

7. (amended) A crystalline form according to claim 3 of the methanesulfonic acid addition salt of a compound of formula I, which shows in an X-ray diffraction diagram lines having a relative line intensity, as compared to the most intense line in the diagram, of about 20 or more at the following

angles of refraction  $2\theta$  :  $9.7^\circ$ ,  $13.9^\circ$ ,  $14.7^\circ$ ,  $17.5^\circ$ ,  $18.2^\circ$ ,  $20.0^\circ$ ,  $20.6^\circ$ ,  $21.1^\circ$ ,  $22.1^\circ$ ,  $22.7^\circ$ ,  $23.8^\circ$ ,  $29.8^\circ$  and  $30.8^\circ$ .


B2  
8. (amended) A crystalline form according to claim 5 of the methanesulfonic acid addition salt of a compound of formula I, which has a melting point of about  $217^\circ\text{C}$ , defined as the start of melting in the differential scanning calorimetry diagram, and which shows essentially the following X-ray diffraction diagram as illustrated in Figure 2B

FB  
4/6/03



wherein the angle of refraction,  $2\theta$ , is plotted on the horizontal axis and the relative line intensity on the vertical axis.

B3  
10 12. (amended) A process for the preparation of the  $\beta$ -crystal form of the methanesulfonic acid addition salt of a compound of formula I




which comprises

a) digesting another crystal form or an amorphous starting material of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent in suspension at a temperature between  $20$  and  $50^\circ\text{C}$ , or

B<sup>2</sup> b) dissolving another crystal form or an amorphous starting material of the methanesulfonic acid addition salt of a compound of formula I, in a polar solvent at a suitable temperature of 25°C up to the reflux temperature of the reaction mixture, and then initiating crystallisation by adding a small amount of the β-crystal form as seed crystal at a temperature between 20 and 70°C.


B<sup>4</sup> 13. (newly added) A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 90% by weight crystals of the β-modification and remains dry at 93% relative humidity and 25°C.

1<sup>2</sup> 14. (newly added) A method for treating a tumor disease in a patient, which comprises administering to the patient an effective amount of a compound of the formula



in its β-crystal modification.

1<sup>3</sup> 15. (newly added) A crystalline form of the methanesulfonic acid addition salt of a compound of formula



which displays x-ray diffraction peaks at 9.7° and 20.0° 2 theta.

1<sup>4</sup> 16. (newly added) A crystalline form of claim 15 which displays x-ray diffraction peaks having a relative line intensity, as compared to the most intense line in the diagram, of about 20 or more at the following angles of refraction 2 theta : 9.7°, 13.9°, 14.7°, 17.5°, 18.2°, 20.0°, 20.6°, 21.1°, 22.1°, 22.7°, 23.8°, 29.8° and 30.8°.

#### STATUS OF THE CLAIMS

Claims 1-8 and 12-16 will be pending in this application upon entry of this amendment.